N

NewAmsterdam Pharma Company NV
NASDAQ:NAMS

Watchlist Manager
NewAmsterdam Pharma Company NV
NASDAQ:NAMS
Watchlist
Price: 33.32 USD -4.28% Market Closed
Market Cap: $3.8B

Operating Margin

-116.7%
Current
Declining
by 51.9%
vs 3-y average of -64.8%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-116.7%
=
Operating Income
€-146.9m
/
Revenue
€107.1m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-116.7%
=
Operating Income
$-146.9m
/
Revenue
€107.1m

Peer Comparison

Country Company Market Cap Operating
Margin
NL
NewAmsterdam Pharma Company NV
NASDAQ:NAMS
3.8B USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
389.3B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.3B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
170.5B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.2B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.4B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.4B USD
Loading...

Market Distribution

Lower than 93% of companies in Netherlands
Percentile
7th
Based on 596 companies
7th percentile
-116.7%
Low
-54 745% — 1.6%
Typical Range
1.6% — 13.6%
High
13.6% — 288.5%
Distribution Statistics
Netherlands
Min -54 745%
30th Percentile 1.6%
Median 8.1%
70th Percentile 13.6%
Max 288.5%

NewAmsterdam Pharma Company NV
Glance View

Market Cap
3.8B USD
Industry
Biotechnology

NewAmsterdam Pharma Company NV is forging its path in the biotech industry with a focus on developing transformative therapies aimed at combating cardiovascular diseases. Emerging from the innovative medical landscape in the Netherlands, the company's keystone is its investigational drug obicetrapib, designed to address the pervasive issue of cardiovascular conditions by significantly lowering LDL cholesterol levels. Through its strategic partnerships and rigorous clinical trials, NewAmsterdam Pharma is committing substantial resources to redefining treatment options for this worldwide health threat. By zeroing in on cholesterol reduction, the company aims to meet an unrelenting demand within the healthcare sector for more effective and accessible cholesterol management solutions. The company’s business model revolves around the commercialization of its proprietary drugs while leveraging collaborations with major pharmaceutical entities to expand its pipeline and market reach. By investing heavily in research and development, NewAmsterdam Pharma believes that it can not only improve global health outcomes but also establish a sustainable revenue stream through the licensing of its compounds and successful drug launches. Capitalizing on both private investments and strategic alliances, the company makes money by bringing its innovations from the lab to the market, thus addressing a critical medical need with the potential to reduce healthcare costs associated with long-term cardiovascular care. Through diligence and determination, NewAmsterdam Pharma is poised to potentially change the landscape of cardiovascular therapy, converting scientific breakthroughs into lifelines for patients worldwide.

NAMS Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-116.7%
=
Operating Income
€-146.9m
/
Revenue
€107.1m
What is NewAmsterdam Pharma Company NV's current Operating Margin?

The current Operating Margin for NewAmsterdam Pharma Company NV is -116.7%, which is below its 3-year median of -64.8%.

How has Operating Margin changed over time?

Over the last 6 months, NewAmsterdam Pharma Company NV’s Operating Margin has decreased from -3.8% to -116.7%. During this period, it reached a low of -125.7% on Jul 30, 2023 and a high of -3.8% on Dec 31, 2022.

Back to Top